Summary
The blood clearance and the urinary excretion of the bone scanning complex technetium-tin-methylene-diphosphonate (99mTc-Sn-MDP) administered intravenously have been measured in 27 normal subjects and 104 patients with post-menopausal osteoporosis, osteomalacia, primary hyperparathyroidism, Paget's disease, pagetoid metastases of prostatic cancer, osteolyses, chronic renal failure, and liver cirrhosis to quantitate the skeletal uptake of the radiopharmaceutical.
Kinetic analysis of the data was performed in terms of a four-compartment model; correspondent rate constants and fitted values were estimated.
In normal subjects the whole-body retention (WBR) up to 24 h was 33.3%±7.4 SD, whereas significantly more elevated values were observed in several pathological conditions, the highest values being ascertained in patients with pagetoid metastases, primary hyperparathyroidism, and chronic renal failure and whenever large osteoid seams were present.
Differences were found between osteoporosis and osteomalacia, monostotic and polyostotic Paget's, pagetoid and osteolytic metastases of bone.
In Paget's disease significant correlations have been observed between WBR and the exchangeable calcium pool, WBR and the serum alkaline phosphatase, and WBR and the urinary excretion of hydroxyproline.
Kinetic analysis demonstrated that WBR provided overestimate of the skeletal retention by an average of 16%, the retention in the “extravascular space” being greater in patients with chronic renal failure.
This simple method shows significant promise for a quantitative approach to the skeletal turnover in metabolic bone disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Krishnamurthy, G.T., Brickman, A.S., Blahd, W.H.: Technetium-99m-Sn-pyrophosphate pharmacokinetics and bone image changes in parathyroid disease, J. Nucl. Med.18:236–242, 1977
Sy, W.M., Mittal, A.K.: Bone scan in chronic dialysis patients with evidence of secondary hyperparathyroidism and renal osteodystrophy, Br. J. Radiol.48:878–884, 1975
Wiegmann, T., Rosenthall, L., Kaye, M.: Technetium-99m-pyrophosphate bone scans in hyperparathyroidism, J. Nucl. Med.18:231–235, 1977
Fogelman, I., Bessent, R.G., Turner, J.A., Citrin, D.L., Boyle, I.T., Greig, W.R.: The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease, J. Nucl. Med.19:270–275, 1978
Subramanian, G., McAfee, J.G., Blair, R.J., Kallfelz, F.A., Thomas, F.D.: Technetium-99m-methylene diphosphonate a superior agent for skeletal imaging: Comparison with other technetium complexes, J. Nucl. Med.16:744–755, 1975
Aubert, J.P., Milhaud, G.: Méthode de mésure des principales voies du métabolisme calcique chez l'homme, Bioch. Biophys. Acta.39:122–139, 1960
King, E.J.: Plasma alkaline phosphatase in disease, Br. Med. Bull.9:160–164, 1953
Neuman, R.E., Logan, M.A.: The determination of hydroxyproline, J. Biol. Chem.184:299–306, 1950
Fletcher, R., Reeves, C.M.: Function minimization by conjugate gradients, Comput. J.7:149–154, 1964
Caniggia, A., Gennari, C.: Kinetics and intestinal absorption of32P-EHDP in man. Calcif. Tissue Res. [Suppl.].22:428–429, 1977
Tofe, A.J., Francis, M.D.: Optimization of the ratio of stannous tin: Ethane-1-hydroxy-1,1-diphosphonate for bone scanning with99mTc-pertechnetate, J. Nucl. Med.15:69–74, 1974
Francis, M.D., Slough, C.L., Tofe, A.J.: Factors affecting uptake and retention of technetium-99m-diphosphonate and 99m-pertechnetate in osseous, connective and soft tissues, Calcif. Tiss. Res.20:303–311, 1976
Bisaz, S., Jung, A., Fleisch, H.: Uptake by bone of pyrophosphate, diphosphonates and their technetium derivatives, Clin. Sci. Mol. Med.54:265–272, 1978
Caniggia, A., Gennari, C.: Diagnostic différentiel des ostéomalacies par les études cinètiques à l'aide du Calcium 45 et du Calcium 47. In D.J. Hioco (ed): L'ostéomalacie, pp. 256–268. Masson et Cie, Paris, 1967
Nagant de Deuxchaisnes, Ch., Krane, S.M.: Paget's disease of bone; Clinical and metabolic observations, Medicine (Baltimore)43:233–266, 1964
Anderson, J., Osborne, S.B., Tomlinson, R.W.S., Wall M.: Calcium dynamics of the gastro-intestinal tract and bone in primary hyperparathyroidism, Q. J. Med.38:421–438, 1963
Haimovitz, A., Horwith, M.: The miscible calcium pool in metabolic bone disease, in particular acromegaly, J. Clin. Endocrinol. Metab.24:4–14, 1964
Miravet, L., Hioco, D., Bordier, Ph.: Etude cinétique avec le45Ca dans l-hyperparathyroïdie avec ou sans lésions osseuses et dans l'hypoparathyroïdie. In C.J. Richelle, M.J. Dallemagne (eds.): Calcified Tissues, pp. 437–449. Liège ed., Colect. des colloques de l'Université, 1965
Nordin, B.E.C., Smith, D.A.: Pathogenesis and treatment of osteomalacia. In D.J. Hioco (ed.): L'ostéomalacie, pp. 379–399. Masson et Cie, Paris, 1967
Joplin, G.F., Robinson, C.J., Melvin, K.E.W., Thompson, G.R., Fraser, R.: Results of tracer studies in osteomalacia. In D.J. Hioco (ed.): L'ostéomalacie, pp. 249–256. Masson et Cie, Paris, 1967
Fogelman, I., McKillop, J.H., Bessent, R.G., Boyle, I.T., Turner, J.C., Greig, W.R.: The role of bone scanning in osteomalacia, J. Nucl. Med.19:245–248, 1978
Nordin, B.E.C.: Metabolic Bone and Stone Disease. Churchill Livingstone, Edinburgh and London, 1973
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Caniggia, A., Vattimo, A. Kinetics of99mTechnetium-Tin-methylene-diphosphonate in normal subjects and pathological conditions: A simple index of bone metabolism. Calcif Tissue Int 30, 5–13 (1980). https://doi.org/10.1007/BF02408600
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02408600